Clinical Trials

Find a Parkview Health Clinical Trial

62 results found

Current Studies

A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)

Primary Outcome Measures: Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) [ Time Frame: Up to approximately 5 years ] ORR is defined as the percentage of participants with Complete...

View Details

Current Studies

Cryotherapy Ablation Therapy for the Treatment of Esophageal Cancer: A Retrospective Review

Primary: to assess the efficacy of cryoablation therapy in the treatment of esophageal adenocarcinoma as adjuvant, neoadjuvant or palliative therapy. Secondary: to assess the safety of cryoablation therapy in the treatment of esophageal cancer

View Details

Current Studies

An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Primary Objectives - Objective: To compare the HIF triplet to the doublet with respect to PFS per RECIST 1.1 as assessed by BICR. - Hypothesis (H1): The HIF triplet is superior to the doublet with respect to PFS per RECIST 1.1 by BICR in advanced ccRCC patients with IMDC intermediate/poor risk. -...

View Details

Current Studies

Surveillance AFter Extremity Tumor surgerY (SAFETY) International Randomized Controlled Trial

Feasibility Research Objectives For the purposes of the pilot phase, the primary objective will be to determine whether it is feasible to conduct a large multi-center RCT that will evaluate the impact of surveillance strategies on patient survival following extremity STS surgery. To do so, we will...

View Details

Current Studies

A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection (PUNCH)

Primary Objective: To evaluate the safety and tolerability of RBX2660 in subjects with recurrent CDI. Secondary Objectives: 1. To evaluate the efficacy of RBX2660 in preventing recurrent episodes of CDI through 8 weeks after treatment. 2. To evaluate the sustained clinical response rate of...

View Details

Current Studies

A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia

Primary Outcome Measures Incidence of adverse events following administration of BBP-671 (Time Frame= 43 day) BBP-671 concentration dependent change in change from baseline in QTcF (Time Frame= 43 days) Pharmacokinetic Assessments: Cmax (Time Frame= 43 days) Time to maximum concentration...

View Details

Current Studies

Integrated Cancer Repository for Cancer Research (iCaRe2)- Subproject: Pancreatic Cancer Collaborative Registry

OBJECTIVES: Develop Integrated Biomedical Computing Tools (IBCT) for the better understanding and treatment of pancreatic cancer by using the power of computer and informatics sciences. Continue development of the Pancreatic Cancer Collaborative Registry (PCCR) infrastructure to act as a...

View Details

Current Studies

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Primary Objectives: To centrally test resected NSCLC for genetic mutations to facilitate accrual to randomized adjuvant studies. To obtain clinically annotated tumor tissue and patient-matched non-malignant DNA from peripheral blood, as well as detailed epidemiologic and clinical follow-up data, to...

View Details

Current Studies

Colorectal Endoscopic Mucosal Resection: A Chart Review Study of Outcomes

This study will determine recurrence and complication rates for those that have undergone endoscopic mucosal resection of colorectal polyps at Parkview Regional Medical Center.

View Details

Current Studies

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

Primary Aim 1. Determine the association of GEP test result with SLNB surgical decisions in patients with SLNB-eligible T1-T2 melanoma Primary Aim 2: Track and evaluate 5-year clinical outcomes for patients in each GEP subclass, including those who did and did not undergo SLNB and those with T3-T4...

View Details

Current Studies

Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy

The purpose of this study is to assess correlations between expression of blood serum biomarkers and cognitive impairment (CI) in patients with colorectal cancer throughout and following chemotherapy treatment. Our primary goal is to establish a panel of biomarkers that predict CI that can be...

View Details

Current Studies

Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Change and Improve Outcomes in Persons With First-Detected Atrial Fibrillation

Determine if early treatment with dronedarone is superior to usual care for the prevention of cardiovascular hospitalization or death from any cause in patients with first-detected atrial fibrillation.

View Details

Current Studies

Clinical efficacy and safety of a novel over-the-scope Gastroduodenal Full Thickness Resection Device (gFTRD) for the treatment of upper gastrointestinal tract lesions: A Multicenter Experience

The main endpoint is the technical success rate of EFTR of UGIT lesions using gFTRD including A. Technical success B. Histological margin Secondary end points include: A. Adverse events B. Procedure time C. Residual or recurrence of lesion on repeat endoscopy

View Details

Current Studies

A Phase 3 Randomized Study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with Muscleinvasive Bladder Cancer (KEYNOTE-905)

- Objective: To compare pathologic complete response (pCR) rates obtained in Arm A (preoperative pembrolizumab and RC+PLND) and Arm B (RC+PLND), based on central pathologic review, evaluated in participants whose tumors express PD-L1 CPS ≥10 and all participants, irrespective of CPS score. -...

View Details

Current Studies

Quality of life assessment in patients receiving cryotherapy in addition to chemotherapy for palliation of unresectable esophageal or gastroesophageal cancer

Primary Objective: To determine the effect of cryoablation combined with chemotherapy on the quality of life (QOL) of patients with non-resectable esophageal or gastroesophageal cancer. Secondary Objective: To determine the effect of cryotherapy on dysphagia scores To describe the safety profile...

View Details

Current Studies

Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma

Primary Endpoint: To identify a gene expression and/or mutational profile that can separate primary cSCC tumors that have a high risk of recurrence compared to primary cSCC tumors that have a low risk of recurrence using RT-PCR and RNA sequencing (RNASeq). Secondary Endpoint: To validate the...

View Details

Current Studies

A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease

Primary Objective To compare the rate of molecular response 4.5 (MR4.5) after 12 months of combination therapy with ruxolitinib plus a TKI (dasatinib or nilotinib) versus a TKI alone, based on local PCR testing to measure BCR-ABL transcripts in chronic phase CML patients with molecular evidence of...

View Details

Current Studies

Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions (CLIMB)

Primary Outcome Measures: Accuracy of PCL diagnosis [Time Frame: 48 months] Diagnostic accuracy of confocal laser endomicroscopy and/or cyst fluid molecular markers and/or composite clinical and imaging features for the diagnosis of mucinous PCLs, PCLs with malignant potential, specific PCL types,...

View Details

Current Studies

CT vs. Endoscopic Ultrasonography in Tumor Discovery and Diagnosis: A Chart Review Study

To identify the incidence of and variables associate with those patients found to have pancreatic tumors upon Endoscopic Ultrasound that were unidentifiable on CT/MRI imaging.

View Details

Current Studies

A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)

Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) [Time Frame: Up to approximately 38 months] Overall Survival (OS) [Time Frame: Up to approximately 46 months] Secondary: Progression-Free Survival (PFS) Per Response Evaluation...

View Details

Current Studies

A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma

Co-primary Objectives To determine the progression free survival (PFS) for paclitaxel with and without nivolumab in subjects with taxane na�ve angiosarcoma. To determine the overall response rate (ORR) of nivolumab in combination with cabozantinib in patients with taxane pre-treated...

View Details

Current Studies

Incidence and Risk Factors for the Recurrence of Ampullary Polyps after Endoscopic Papillectomy: A Multicenter, Retrospective Study

Central Hypothesis: Histological and endoscopic features of the papilla impact recurrence. Recurrence is higher in patients with Familial adenomatous polyposis than with sporadic adenomas of the papilla. Specific Aim #1: Rate of recurrence of ampullary adenomas in patients with and without...

View Details

Current Studies

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age greater than/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Primary Objective: To compare the progression-free survival (PFS) in patients with newly diagnosed advanced stage classical Hodgkin lymphoma randomized to N-AVD (nivolumab, doxorubicin, vinblastine, dacarbazine) versus that obtained with BV-AVD (brentuximab vedotin, doxorubicin, vinblastine,...

View Details

Current Studies

A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA

Primary Objectives Phase II To assess the efficacy of concurrent definitive therapy followed by nivolumab compared with concurrent definitive therapy followed by observation in terms of progression-free survival (PFS). Phase III To assess the efficacy of concurrent definitive therapy followed by...

View Details

Current Studies

MK3475 Protocol B96: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96)

To compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival (PFS) per RECIST 1.1 as assessed by the investigator Hypothesis (H1): pembrolizumab plus paclitaxel with or without bevacizumab is...

View Details

Current Studies

EF-36/Keynote B36: A Pilot, Single Arm, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Intrathoracic Non-small Cell Lung Cancer

Primary Outcome Measures : Objective Response Rate (ORR) [ Time Frame: 24 months ] ORR will be measured from the date of enrollment to date of progression (in months) based on RECIST 1.1 criteria. The analysis will include patients with PD-L1 expression TPS≥1-49 percent and TPS≥50...

View Details

Current Studies

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry

Primary: Create a large scale, population-based registry of full genome expression data matched with clinical data to investigate new gene associations with prognostic and/or predictive value Utilize registry data to graduate identified expression signatures into subset trials and recommend...

View Details

Current Studies

Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure (ALLEVIATE-HF)

Primary Outcome Measures: *Safety of patient management pathway - Proportion of medication interventions with associated medication intervention related serious adverse events (Time Frame: Up to 3 years) *The proportion of medication interventions with one or more associated medication...

View Details

Current Studies

Endoscopic Stenting in Esophageal Cancer: A Chart Review Study

It is the aim of this study to analyze the outcomes of endoscopic esophageal stent placement in those with esophageal cancer

View Details

Current Studies

Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia (NODE-303)

Primary: 1. The primary objective is to evaluate the safety of self-administered etripamil nasal spray (NS) outside of the clinical setting. Secondary Objectives: 1. To evaluate the efficacy of self-administered etripamil NS outside of the clinical setting, and 2. To evaluate the impact of...

View Details

Current Studies

A Phase 3, Randomized, Double-blind, Multicenter Study of TSR-042 plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer

To compare the progression-free survival (PFS) of treatment with dostarlimab plus carboplatin-paclitaxel to treatment with placebo plus carboplatin-paclitaxel, as assessed by the Investigator per RECIST v.1.1, in the following: [ Time Frame: Up to 5 years ] * All subjects with recurrent or...

View Details

Current Studies

MK6482-011 An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti- PD-1/L1 Therapy

Primary Objective: -To compare MK- 6482+lenvatinib to cabozantinib with respect to PFS per Response Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR). -Hypothesis (H1): MK-6482+lenvatinib is superior to cabozantinib with respect to PFS per RECIST 1.1 by...

View Details

Current Studies

A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) plus Pembrolizumab (MK-3475) Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (6482-022)

Primary To compare disease-free survival (DFS) as assessed by investigator for participants treated with belzutifan plus pembrolizumab versus those receiving placebo plus pembrolizumab Hypothesis (1): Belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect to...

View Details

Current Studies

A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Investigational Agents for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98)

Primary Outcome Measures: : Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) [ Time Frame: Up to 21 days in Cycle 1 (Cycle 1 = 21 days) ] DLTs = ≥1 of the following treatment-related toxicities: Grade (G)4 nonhematologic toxicity; G4 hematologic toxicity lasting >7 days...

View Details

Current Studies

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

Primary Objective To assess whether adjuvant therapy with erlotinib will result in improved overall survival (OS) over observation for patients with completely resected stage IB (4 cm)-IIIA EGFR mutant NSCLC (confirmed centrally) following complete resection and standard post-operative...

View Details

Current Studies

Endoscopic Mucosal Resection vs. Colon Resection: A Retrospective Efficacy and Cost Comparison Analysis in a Tertiary Community Referral Setting

Objectives 1. To compare efficacy of EMR to Laparoscopic Colon Resection (hemicolectomy) in the treatment of benign, flat colon polyps 2. To compare safety of EMR to Laparoscopic Colon Resection (hemicolectomy) in the treatment of benign, flat colon polyps 3. To compare cost...

View Details

Current Studies

Phase 2 Trial Evaluating the Safety and Tolerability of Intratumoral Injections of NanoPac� With Standard of Care Therapy in Subjects With Lung Cancer

The primary objective of this study is to evaluate the safety and tolerability of NanoPac injected into lung cancer lesions by EBUS-TBNI on multiple (up to three) occasions, each injection procedure administered 4 weeks apart. Safety and tolerability will be assessed for 24 weeks following first...

View Details

Current Studies

Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure - Thrombolysis in Myocardial Infarction 68 ( DAPA ACT HF-TIMI 68)

PRIMARY OBJECTIVE To assess the effect of in-hospital initiation of dapagliflozin, as compared with placebo, on the clinical outcomes of cardiovascular death or worsening heart failure in patients who have been stabilized during hospitalization for acute heart failure. To evaluate the safety and...

View Details

Current Studies

Endoscopic Repair of Esophageal Perforation: A Chart Review Study

It is the aim of this study to analyze the outcomes of esophageal perforation with esophageal fully covered metal stents or endoscopic suturing.

View Details

Current Studies

A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

Primary Objective To evaluate the response rate (confirmed, complete or partial) of AMG 510 in participants with KRASG12C mutated Stage IV or recurrent non-squamous non-small cell lung cancer (NSCLC). The response rates will be evaluated separately with cohorts defined as: i. Cohort 1 (co-mutation...

View Details

Current Studies

A Phase 3 Study of Pembrolizumab (MK-7339) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib Compared with Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)

Primary: To compare pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab plus olaparib to concurrent chemoradiation therapy followed by durvalumab with respect to progression-free survival per RECIST 1.1 as assessed by blinded independent central review. To compare...

View Details

Current Studies

A Novel Retraction Device for Endoscopic Submucosal Dissection (ESD): A Multicenter Retrospective Study

Specific Study Aims: Study Aim 1: The primary aim of this study was to determine the technical success of ESD using the retraction device by determining completeness of the resection (�en-bloc vs incomplete). Study Aim 2: We aim to determine the safety of the device with regards to perforation and...

View Details

Current Studies

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Primary Objective a To evaluate the RECIST v1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy. b To evaluate the overall response rate (ORR, per criteria in Section 10.8) in patients with gestational...

View Details

Current Studies

(A Randomized, Comparative Effectiveness Study of Staged Complete Revascularization with Percutaneous Coronary Intervention to Treat Coronary Artery Disease vs Medical Management Alone in Patients with Symptomatic Aortic Valve Stenosis undergoing Elective Transfemoral Transcatheter Aortic Valve Replacement (COMPLETE TAVR)

Primary Objective: To determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the...

View Details

Current Studies

Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0)

Primary Objective Non-inferiority of partial breast irradation (PBI) and concurrent compared to sequential chemotherapy with respect to acute grade 3-4 radiation toxicity Secondary Objectives Evaluate and compare any first tumor recurrence (local plus distant) between arms of the study. Evaluate...

View Details

Current Studies

Multi-center Prospective Evaluation of the Clinical Utility of Endoscopic Submucosal Dissection (ESD) in the Western Population

Primary An Excision of the targeted lesion in a single specimen Secondary Rate of R0 resection Time Frame 3-4 hours when all vertical and horizontal margins are negative Rate of R1 resection Time Frame 3-4 hours complete resection with no grossly visible lesion defined by...

View Details

Current Studies

Endoscopic Submucosal Dissection for Resection of T1b N0 Esophageal Cancer: A Retrospective Multicenter Trial

Central Hypothesis: Endoscopic submucosal dissection with and without adjuvant therapy (XRT, chemotherapy based on final precise pathology) allows for adequate management of T1b N0 EAC and SCC. Specific Aim #1: To assess the long-term outcomes (local and metastatic recurrence) of ESD +/- adjuvant...

View Details

Current Studies

A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma

Primary: Progression-free survival (PFS) To determine the efficacy by progression free survival (using investigator assessment of scans according to RECIST v1.1) of oregovomab compared to placebo when administered with background chemotherapy (paclitaxel/carboplatin) to subjects with...

View Details

Current Studies

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Primary Objective: To evaluate whether adjuvant therapy with crizotinib will result in improved overall survival (OS) for patients with stage IB greater than or equal to 4cm, II and IIIA, ALK-positive NSCLC following surgical resection. Secondary Objectives: To evaluate and compare disease-free...

View Details

Current Studies

HPS 4/TIMI 65 ORION 4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease.

The HPS-4/TIMI 65/ORION-4 study aims to provide evidence about both the efficacy and safety of inclisiran. Consistent with relevant guideline recommendations for people with vascular disease, it is intended that participants be on intensive background LDL-lowering therapy, at screening. The...

View Details

Current Studies

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women with Recurrent or Persistent Endometrial Cancer

Primary Objective To compare the efficacy of single-agent olaparib and the combination of olaparib and cediranib (and potentially other combination arms that may be added by subsequent amendment) versus single agent cediranib as measured by progression free survival (PFS), in patients with...

View Details

Current Studies

Parkview Health Falls Registry

Primary: * To identify risk factors in patient history among patients evaluated at the Fall Prevention Clinic. Secondary: * To compare the characteristics of adult patients who experience falls v/s those who do not. * To review findings on examination (general and neurological) and testing...

View Details

Current Studies

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

Primary Objective of the Master Protocol (LungMAP) The primary objective of this screening study is to test patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol. Secondary Objectives a....

View Details

Current Studies

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Primary Objective To examine if letrozole monotherapy/maintenance is non-inferior to IV paclitaxel/carboplatin and maintenance letrozole with respect to PFS in women with stage II-IV primary low-grade serous carcinoma of the ovary or peritoneum after primary surgical cytoreduction. Secondary...

View Details

Current Studies

A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors

Primary Outcome Measures : Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessment [ Time Frame: Up to end of treatment (average 3 years) ] ORR, is defined as the rate of the overall best response, complete response (CR) or...

View Details

Current Studies

Duodenal endoscopic submucosal dissection, western experience

The purpose of this study is to explore the ESD feasibility and efficacy in duodenal tumors treatment.

View Details